Send to:

Choose Destination
See comment in PubMed Commons below
Int J Gynaecol Obstet. 2012 Nov;119(2):178-81. doi: 10.1016/j.ijgo.2012.06.007. Epub 2012 Aug 18.

Post-vaccination anti-human papillomavirus antibody seroprevalence among Czech teenaged girls and women.

Author information

  • 1Immunological Laboratory, Interimun spol. s r.o., Pardubice, Czech Republic.



To evaluate seroprevalence among Czech girls and women previously vaccinated against human papillomavirus (HPV).


A commercial enzyme-linked immunosorbent assay was used to determine the level of antibodies and seropositivity, with no genotype specification.


A group of 356 teenaged girls and women with a mean age of 19.5 years (95% confidence interval [CI], 18.9-20.1 years) was found to have 94.1% HPV seropositivity (95% CI, 91.1%-96.3%) up to 3.5 years after vaccination. The vaccine-specific total seropositivity rates were 98.0% and 85.0% among quadrivalent vaccinees (Gardasil; Merck, Whitehouse Station, NJ, USA) and bivalent vaccinees (Cervarix; GlaxoSmithKline, Brentford, UK), respectively. Adjusting for age and post-vaccination time period, an expected 2:1 (quadrivalent:bivalent) ratio of the geometric mean concentrations of total HPV-specific antibodies induced by the vaccines was observed. The antibody avidity remained almost unchanged up to 3.5 years later. Nevertheless, the mean avidity index was significantly higher among quadrivalent vaccinees (2.50 M GuHCl/mL; 95% CI, 2.42-2.58 M GuHCl/mL) than bivalent vaccinees (2.09 M GuHCl/mL; 95% CI, 2.01-2.17 M GuHCl/mL).


High anti-HPV seroprevalence at a level related to the valency of vaccine used was achieved among Czech teenaged girls and women up to 3.5 years after vaccination.

Copyright © 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk